NeoGenomics Inc. (NEO)
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Neo Performance Materials Q2 Earnings Call Highlights
Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.
NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NeoGenomics Q2 Earnings Call Highlights
NeoGenomics NASDAQ: NEO raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing.
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
Neo Energy Metals shares surge 33% as ex-Sibanye chief Froneman joins as chairman
Neo Energy Metals PLC (LSE:NEO) shares surged 33% to 11.02p after the uranium and gold developer announced a sweeping boardroom overhaul headlined by the appointment of Neal Froneman, the former chief executive of mining giant Sibanye-Stillwater, as independent non-executive chairman. Froneman, who led Sibanye-Stillwater from its formation in January 2013 until September 2025, oversaw its transformation from a 1.5 million-ounce South African gold producer into a globally diversified metals company and the world's largest primary producer of platinum group metals.
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)
NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago.
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
NEO launches PanTracer Pro, a pan-solid tumor assay built to streamline genomic testing and speed treatment decisions in advanced cancers.
NeoGenomics: Distribution Moat In Community Oncology
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO's clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration.
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
